louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04152122: A Novel Dynamic Random-dot Stereopsis Assessment to Measure the Stereopsis in Intermittent Exotropia
Official title: A Novel Dynamic Random-dot Stereopsis Assessment to Measure the Stereopsis in Intermittent Exotropia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dynamic Stereopsis in Intermittent Exotropia Patients
Lead sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Sponsor class: OTHER
First posted: 2019-11-05
Enrollment: 133
Sex: ALL
Minimum age (years): 5
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 83 cases X(T) patients and 50 normal subjects were enrolled in the study.

Brief summary: A novel dynamic random-dot stereopsis test that included motion + disparity (MD), motion (M), and disparity (D), in which the disparity cues range from 200 to 1200 arc-seconds was used. The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.


Eligibility criteria: Inclusion Criteria:

X(T) groups were as follows:

1. near and distance exodeviation angles greater than 5 prism degrees (PD) and alternate cover tests and X(T) diagnosis by an experienced doctor;
2. between 5 and 30 years old;
3. 0.0 or better best corrected visual acuity (BCVA; logMAR, log of the minimum angle of resolution);
4. absence of other ocular disorders or other systemic diseases.

Normal group were as follows:

1. between 5 and 30 years old;
2. 0.0 or better logMAR BCVA;
3. near and distance exodeviation angles less than 5 PD and alternate cover tests; and
4. no history of any ocular pathology or systemic disease.

Exclusion Criteria:

X(T) groups were as follows:

1. near and distance exodeviation angles less than 5 prism degrees (PD)
2. younger than 5 or older than 30 years old;
3. less than 0.0 or better best corrected visual acuity (BCVA; logMAR, log of the minimum angle of resolution);
4. has other ocular disorders or other systemic diseases.

Normal group were as follows:

1. younger than 5 or older than 30 years old;
2. less than 0.0 or better best corrected visual acuity (BCVA; logMAR, log of the minimum angle of resolution);
3. near and distance exodeviation angles more than 5 PD and alternate cover tests;
4. has history of any ocular pathology or systemic disease.

Primary outcomes:
measure: The mean reciprocal value of stereopsis
timeFrame: 1st day
measure: The mean reciprocal value of stereopsis
timeFrame: 2nd month
measure: The mean reciprocal value of stereopsis
timeFrame: 6th month
measure: The mean reciprocal value of stereopsis
timeFrame: 12th month
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Opthalmic Center
state: Guangdong
Study officials:
References:
Clinical trial NCT00530322: Adhesion Formation Following Laparoscopic and Open Colorectal Surgery
Official title: Adhesion Formation Following Laparoscopic and Open Colorectal Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adhesions
Keywords: Adhesions
Laparoscopy
Colorectal surgery
Colorectal disease
Lead sponsor: University of Surrey
Sponsor class: OTHER
Collaborators: name: Ethicon Endo-Surgery
First posted: 2007-09-17
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: To ascertain whether there are fewer adhesions (internal scars) formed following laparoscopic (key-hole) surgery for colorectal diseases than traditional open surgery.


Eligibility criteria: Inclusion Criteria:

* Previous elective colonic or rectal resection
* Having a further operative intervention at which time a laparoscopy can be performed

Exclusion Criteria:

* Children \<18
* Further surgery not relating to the primary colorectal surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Guildford
country: United Kingdom
facility: The Royal Surrey County Hospital
state: Surrey
Study officials:
affiliation: The Royal Surrey County Hospital
name: Timothy A Rockall, FRCS
role: STUDY_DIRECTOR
References:
Clinical trial NCT06294522: Reconstruction of Nasal Floor for Three-dimensional Repair of Alveolar Cleft
Official title: Lecturer of Oral and Maxillofacial Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alveolar Cleft
Keywords: alveolar cleft
nasal floor support
autogenous bone graft
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-03-05
Enrollment: 16
Sex: ALL
Minimum age (years): 9
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: reconstruction of alveolar cleft with autogenous bone after elevation of mucoperiosteal flap and suturing of nasal floor and palatal flap

Detailed description: gingival mucoperiosteal flaps are designed along the cleft margins and elevated medial and lateral mucoperiosteal flaps are generated from the cleft and the gingival sulcus of the teeth. To obtain adequate mobility of the posterior flap, the flap must be extended to the first or the second molar and back-cut up to the buccal sulcus while taking care not to injure the alveolar bone covering the roots of the teeth. These flaps are raised up to and around the piriform aperture, and then are separated from the nasal mucosa the palatal mucoperiosteal flaps along the cleft margins are then elevated from the palate. After complete exposure of all the bony clefts, the nasal lining of the nostril floor is approximated and sutured, and the palatal flaps are then turned back and sutured to make a soft-tissue pocket. Grafting of the defect is accomplished with cortical bone only from the chin the cortical shelf is prepared to be two layers perpendicular to each other the first one is parallel to the nasal floor and second one is continuous with buccal cortex of alveolar ridge then cancellous bone will be packed under these shelves and be compressed into the cleft defect to maximize the number of osteo-competent cells and the osteoid material per unit graft volume. When packing bone particles, it is better to create the maxilla and alveolar ridges and elevate the depressed nostril by appropriately supporting the nasal base and aligning the symmetry. The rest can then be covered with gingival mucoperiosteal flaps through tension-free transposition

Eligibility criteria: Inclusion Criteria:

patients had alveolar cleft adequate and healthy soft tissue

-

Exclusion Criteria:

* age less than 9 very wide cleft scared soft tissue

Primary outcomes:
measure: recurrence of oronasal fistula
timeFrame: one month
measure: volume of alveolar cleft after reconstruction
timeFrame: immediate and after 6 months
measure: density of bone
timeFrame: Six months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of Dentistry, Tanta University
Study officials:
affiliation: Tanta University
name: mona s sheta
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01981239: Voice Analysis Using the LPC (Linear Predictive Coding)Method for the Prediction of Aspiration
Official title: Voice Analysis Using the LPC (Linear Predictive Coding)Method for the Prediction of Aspiration;Prospective, Positive-controlled, Single-blind, Single Cohort Clinical Study of Efficacy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Deglutition Disorder
Keywords: voice analysis aspiration prediction
Lead sponsor: Ulsan University Hospital
Sponsor class: OTHER
First posted: 2013-11-11
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: It was well known that aspiration is the primary cause of an aspiration pneumonia among the dysphagia patients.

In order to predict the degree of an aspitation,video-fluoroscopic-swallowing study and fiberoptic-endoscopic swallowing evaluation have been developed, but those evaluations are invasive and allowed only in a limited condition.

In this study, as a precedent study for the non-linear analysis, voice analysis using LPC method will be evaluated. The superiority of LPC method will be compared with a spectral analysis using Jitter and Simmer as a positive control.

This clinical study will be performed prospective, positive-controlled, single-blind (i.e. assessor-blind),and single cohort clinical trial for efficacy


Eligibility criteria: Inclusion Criteria:

* Patients who were referred for VFSS

Exclusion Criteria:

* Patients cannot phonate d/t tracheostomy
* Preexisting oro-laryngo-pharyngeal disease
* Patients cannot follow 1 step command
* Patients cannot maintain a phonation for 3 seconds
* Refusal of participation
* Patients who were not classified for the candidate by physicians
* Patients who coughs following drinking of 5ml normal saline

Primary outcomes:
measure: LPC index
timeFrame: one day before or after VFFS
Secondary outcomes:
measure: Spectral Analysis
timeFrame: one day before or after VFFS
measure: LPC anaysis
timeFrame: one day after or before VFSS
measure: Risk group
timeFrame: whithin one hour of VFSS
Other outcomes:
Locations:
city: Ulsan
country: Korea, Republic of
facility: Ulsan University Hospital
Study officials:
affiliation: Ulsan University Hospital
name: Chang Ho Hwang, M.D. & Ph.D.
role: STUDY_DIRECTOR
affiliation: University of Ulsan
name: Hyungseob Han, M.Sc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05547139: Impact of Extended CPAP on Bronchopulmonary Dysplasia
Official title: Impact of Extended CPAP Utilization on Bronchopulmonary Dysplasia in Extremely Premature Infants: A Pilot Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bronchopulmonary Dysplasia
Prematurity
Keywords: Bronchopulmonary dysplasia
Prematurity
High flow nasal cannula
Continuous positive airway pressure
NICU
Lead sponsor: Christiana Care Health Services
Sponsor class: OTHER
First posted: 2022-09-21
Enrollment: 20
Sex: ALL
Minimum age (years): 22
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Infants will be randomized to the usual care group or the protocol care group.
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this pilot study is to compare if keeping infants on CPAP (continuous positive airway pressure) support for an extended period of time until they are 32 weeks corrected gestational age or 1250 grams (approximately 2 pounds and 12 ounces) will decrease their degree of lung disease as compared to weaning their respiratory support to HFNC (high flow nasal cannula).

Detailed description: There are two ways to help premature babies breathe. Both HFNC and CPAP are commonly used in our NICU. CPAP, which helps your baby breathe without a tube in their windpipe (intubation or ventilator), delivers oxygen and air by pressure through either small prongs in the nose or a nose mask, keeping your baby's airways open. HFNC provides heated and humidified oxygen and air by small prongs in the nose that does not use high pressure to the airways. Our goals are to reduce long term complications such as lung disease of prematurity, also called Bronchopulmonary Dysplasia (BPD). BPD causes "lung damage/scarring, need for a ventilator or oxygen, brain/neurological impairment etc. In recent years, HFNC has become a common choice for care. There is no clear agreement in previous research which way may be best to reduce BPD.

Eligibility criteria: Inclusion Criteria:

* babies born at \<30 weeks' gestation
* babies who are extubated to non-invasive ventilation by 32 weeks postmenstrual age

Exclusion Criteria:

* babies born at \<30 weeks' gestation
* requiring less than 2L NC at birth or
* those who are extubated after 32.0 weeks' postmenstrual age
* congenital anomalies
* skeletal disorders
* neuromuscular disorders
* genetic syndromes

Primary outcomes:
measure: Time to reach 2L NC or room air
timeFrame: up to 3 months
Secondary outcomes:
measure: Compliance to protocol and balancing measures
timeFrame: up to 3 months
Other outcomes:
Locations:
city: Newark
country: United States
facility: Christiana Care Health Services, Inc.
state: Delaware
Study officials:
affiliation: Christiana Care Health Services, Inc
name: Kelley Z Kovatis, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Christiana Care Health Services, Inc
name: Anastasiya Latushko
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00445939: A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
Official title: A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Crohn's Disease
Lead sponsor: Abbott
Sponsor class: INDUSTRY
Collaborators: name: Abbott Japan Co.,Ltd
name: Eisai Co., Ltd.
First posted: 2007-03-09
Enrollment: 90
Sex: ALL
Minimum age (years): 15
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.


Eligibility criteria: Inclusion Criteria:

* Crohn's Disease Activity Index (CDAI) score of \>= 220 and \<= 450
* If subjects have previously been administered infliximab, subjects who discontinued use due to a loss of response or intolerance to infliximab therapy

Exclusion Criteria:

* Ulcerative colitis or indeterminate colitis
* History of cancer, lymphoma, leukemia or lymphoproliferative disease, active tuberculosis (TB), or Human immunodeficiency virus (HIV)
* Body weight is below 30 kg
* Surgical bowel resections within the past 6 months
* Females who are pregnant or breast-feeding or considering becoming pregnant during the study

Primary outcomes:
measure: The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4
timeFrame: 4 Weeks
Secondary outcomes:
measure: Clinical Remission (CDAI < 150) at Week 2
timeFrame: Week 2
measure: Clinical Response (CR-70 and CR-100) in Period A
timeFrame: Weeks 2 and Week 4
measure: Clinical Response (CR-70 and CR-100) in Period B
timeFrame: Week 6 and Week 8
measure: Clinical Remission (CDAI <150) at Week 6 and Week 8
timeFrame: Week 6 and Week 8
Other outcomes:
Locations:
city: Aichi
country: Japan
city: Chiba
country: Japan
city: Ehime
country: Japan
city: Fukuoka
country: Japan
city: Hiroshima
country: Japan
city: Hokkaido
country: Japan
city: Hyogo
country: Japan
city: Kagawa
country: Japan
city: Kanagawa
country: Japan
city: Kochi
country: Japan
city: Kyoto
country: Japan
city: Miyagi
country: Japan
city: Okayama
country: Japan
city: Okinawa
country: Japan
city: Osaka
country: Japan
city: Shiga
country: Japan
city: Shizuoka
country: Japan
city: Tokyo
country: Japan
Study officials:
affiliation: Abbott Japan Co.,Ltd
name: Morio Ozawa
role: STUDY_DIRECTOR
References:
citation: Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, Camez A; Study Investigators. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012 Mar;6(2):160-73. doi: 10.1016/j.crohns.2011.07.013. Epub 2011 Aug 26.
Clinical trial NCT01381939: Induction of Labor in Intrahepatic Cholestasis of Pregnancy
Official title: Induction of Labor in Intrahepatic Cholestasis of Pregnancy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intrahepatic Cholestasis
Keywords: Intrahepatic Cholestasis of Pregnancy
Induction of labor
Pregnancy
Caesarian section
Pruritus
IUFD
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2011-06-27
Enrollment: 5000
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Swedish women affected by ICP delivering at Danderyd Hospital between year 2000-2006.

Brief summary: Induction of Labour in Intrahepatic Cholestasis of Pregnancy (ICP) has become a common procedure in management of ICP to avoid fetal complications. Surprisingly, this empirical approach has not been evaluated as to delivery complications and fetal outcome as yet. The investigators now examine weather ICP affects (i) delivery procedures chosen, in particular the incidence of caesarian section, (ii)fetal and maternal outcome in induced labor, and (iii)possible impact of bile acids and UDCA treatment in a retrospective cohort study based on approximately 5000 induced deliveries at Danderyd Hospital, Karolinska Institutet, Stockholm. The investigators analyze data on on previous deliveries, BMI, medical history and medical book data. Primary endpoint is the risk of caesarian section.


Eligibility criteria: Inclusion Criteria:

* ICP during pregnancy and induction of labor ICP and spontaneous delivery No ICP but induction of labor

Exclusion Criteria:

* No ICP spontaneous delivery
* Elective caesarian section

Primary outcomes:
measure: Cesarean section
timeFrame: 32 to 40 weeks
Secondary outcomes:
measure: Bleeding
timeFrame: 32 to 40 weeks
measure: Abruptio placentae
timeFrame: 32 to 40 weeks
measure: APGAR
timeFrame: 32 to 40 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02574039: Oat Phenolics Bioavailability
Official title: Absorption, Metabolism and Excretion of Oat Phenolic Acids in Healthy Men.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: volunteers
oat
phenolic acid
bioavailability
Lead sponsor: University of Reading
Sponsor class: OTHER
Collaborators: name: PepsiCo Global R&D
First posted: 2015-10-12
Enrollment: 7
Sex: MALE
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A diet rich in whole grain is inversely associated with cardiovascular disease risk and this benefit could be partly attributed to the phenolic acid content of whole grains. The exact absorption, metabolism and excretion of whole grain phenolic acids, however, is not fully understood. In a small human intervention trial, the investigators will investigate to what extent phenolic acids from whole grain oats are absorbed, excreted in urine and how they are metabolised.


Eligibility criteria: Inclusion Criteria:

* Males
* 25 to 65 years old

Exclusion Criteria:

* Allergies to oats
* Parallel participation in another research project
* Having flu vaccination or antibiotics within 3 months of trial start
* Taking food supplements within 3 months of trial start
* Past or existing medical history of vascular disease, diabetes, hepatic, renal, gastrointestinal, haematological, neurological, thyroidal disease or cancer

Primary outcomes:
measure: Change from baseline in phenolic acid metabolite excretion
timeFrame: Baseline and 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Reading
country: United Kingdom
facility: Department of Food and Nutritional Sciences
state: Berkshire
Study officials:
References:
Clinical trial NCT05211739: Clinical Assessment of a Daily Wear Monthly Replacement Silicone Hydrogel Toric Contact Lens
Official title: Clinical Assessment of a Daily Wear Monthly Replacement Silicone Hydrogel Toric Contact Lens
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractive Errors
Astigmatism
Keywords: Contact Lenses
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2022-01-27
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical study is to assess the clinical performance of an investigational toric soft contact lens compared to a commercially available toric contact lens in a crossover dispense trial when worn in a daily wear modality for 30 days, each study lens type.

Detailed description: Subjects will be randomized to 1 of 2 crossover wear sequences. Subjects will be expected to attend 5 office visits, for a total individual duration of participation in the study of approximately 60 days.

Eligibility criteria: Key Inclusion Criteria:

* Successful wearers of weekly/monthly toric soft contact lenses in both eyes for a minimum of 5 days per week and 10 hours per day during the past 3 months;
* Best corrected distance visual acuity (as determined by manifest refraction at screening) better than or equal to 20/25 Snellen in each eye.
* Able to wear contact lenses within the range of available sphere \& cylinder power and axes.
* Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

* Daily disposable contact lens wearers.
* Monovision and multifocal contact lens wearers.
* Habitual Biofinity Toric/Biofinity Toric XR contact lens wearers in the past 3 months prior to consent.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Distance Visual Acuity (VA) With Study Lenses
timeFrame: Day 1 and Day 30, each wear period (approximately 30 days)
Secondary outcomes:
Other outcomes:
Locations:
city: Longwood
country: United States
facility: Sabal Eye Care
state: Florida
city: Maitland
country: United States
facility: Drs. Giedd, P.A.
state: Florida
city: Orlando
country: United States
facility: Vision Health Institute
state: Florida
city: Pittsburg
country: United States
facility: Kannarr Eye Care LLC
state: Kansas
city: Willmar
country: United States
facility: Fischer Laser Eye Center
state: Minnesota
city: New York
country: United States
facility: SUNY College of Optometry Clinical Vision Research Center
state: New York
city: Warwick
country: United States
facility: West Bay Eye Associates
state: Rhode Island
Study officials:
affiliation: Alcon Research, LLC
name: Clinical Trial Lead, CRD Vision Care
role: STUDY_DIRECTOR
References: